{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"86.7","value":"74.7"},{"groupId":"OG001","spread":"101.6","value":"59.9"},{"groupId":"OG002","spread":"68.4","value":"65.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"340"},{"groupId":"OG001","value":"314"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 2 (Week 4) pre-dose, Geometric mean"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"116.2","value":"113.9"},{"groupId":"OG001","spread":"280.1","value":"77.5"},{"groupId":"OG002","spread":"137.5","value":"92.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"253"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 4 (Week 12) pre-dose, Geometric mean"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.7","value":"556.9"},{"groupId":"OG001","spread":"38.6","value":"539.3"},{"groupId":"OG002","spread":"36.8","value":"528.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"248"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"title":"Cycle 4 (Week 12) post-dose, Geometric mean"}],"denoms":[{"counts":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"388"},{"groupId":"OG002","value":"142"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Blood sample were collected at pre-specified timepoints and Durvalumab concentrations in serum (ug/mL) were reported over time.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set includes all participants who received at least 1 dose Durvalumab per the study protocol for whom any PK post-dose data were available (ie, at least 1 non-missing post-dose PK result). T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"To evaluate the PK of Durvalumab, samples were collected pre-dose at week 4 and week 12 and post-dose at week 12. Assessed at the final analysis DCO (27Aug2021).","title":"Summary of Durvalumab Concentration Over Time","type":"SECONDARY","unitOfMeasure":"ug/mL"}